“In a new study published in Cancer Research, researchers from the University of Oxford and Moffitt Cancer Center in Florida introduce a novel framework that applies deep reinforcement learning, DRL, (a form of AI) to create adaptive therapy schedules for individual prostate cancer patients. The results indicate that the new adaptive approach could potentially double the time to relapse compared to MTD or non-personalised treatment breaks.”
Read more on Study demonstrates how AI can develop more personalised cancer treatment strategies via University of Oxford.
Family Medicine Residency Site: Abbotsford-Mission 